Sanofi has secured a conditional marketing authorization for Rezurock (belumosudil) in the EU, marking a major step forward in chronic GVHD treatment.
Teva Pharmaceutical is accelerating its Teva’s biosimilars expansion with three major milestones that strengthen its “Pivot to Growth” strategy and reinforce its position in the global biosimilars market.
Government of India is stepping up its push for generic medicines in hospitals, urging healthcare providers to prescribe and stock low-cost alternatives to branded drugs.
AstraZeneca made a major move today with its experimental COPD drug tozorakimab, reporting that the treatment significantly reduced moderate to severe flare ups of chronic obstructive pulmonary disease (COPD) in two late stage Phase III trials.
With Semaglutide India versions hitting the market as the global weight loss and diabetes drug moves off patent, leading cardiology, endocrinology, and diabetology experts from Pune and Mumbai have issued a firm warning...
Lupin has secured US FDA approval for Pitolisant tablets ANDA, marking another step in its push into the central nervous system segment.
India’s healthcare sector is feeling the heat of the helium supply crisis; as global disruptions tied to tensions in the Middle East and restricted trade through the Strait of Hormuz begin to push up MRI scan cost and delay installations of...
Bristol Myers Squibb has secured a major regulatory win as the FDA approves its cancer drug for stage IV. The drug, Opdivo (nivolumab) is for patients with advanced classical Hodgkin lymphoma, marking a shift in how the disease is treated...
Indian pharma manufacturers are pushing for input price caps as raw material costs surge sharply. Smaller companies warn that without support, rising expenses and tight drug price controls could disrupt medicine supply.
Ajanta Pharma, Sun Pharma, and Lupin are in focus as Ozempic Patent Expiry drives surge in pharma stocks ahead of launch, with companies gearing up for semaglutide generics in the fast-growing diabetes and weight-loss market.